联华超市(00980)发布公告，本集团预计截至2025年12月31日止年度的业绩取得归属于本公司股东的净 亏损将较截至2024年12月31日止年度的净亏损明显下降，主要得益于本集团整体战略规划调整，出售子 公司股权收益，以及优化资源配置，减少亏损。 鉴于此，董事会谨此通知股东及潜在投资者，较截至2024年12月31日止年度经审计归属于本公司股东的 净亏损人民币约3.59亿元，本集团预计截至2025年12月31日止年度的业绩取得归属于本公司股东的净亏 损将明显下降，降幅约为35%至55%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於中華人民共和國註冊成立的股份有限公司） （股份代碼：3983） 公告 委託管理富島化工 本次交易 董事會宣佈，於2026年2月28日，本公司、中海石油煉化及富島化工簽訂委託管理協議， 據此，本公司委託中海石油煉化對富島化工日常生產經營進行管理。委託管理協議期限 由2026年3月1日起至2029年2月28日止。 本次交易的原因及好處 鑒於中海石油煉化的全資附屬公司東方石化為富島化工的主要原料供應商，其具備產 業協同優勢，且在富島化工降本增效方面處於更有利位置。此外，東方石化在丙烯腈等 化工產品的生產經營方面擁有先進、成熟且廣泛的能力與經驗。為了進一步推動資源配 置與管理的優化，以及提升富島化工的經營效率，各方已同意訂立本次交易。 上市規則的涵義 於本公告日期，中國海油為本公司的控股股東，中海石油煉化為中國海油的全資附屬公 司。因此，根據上市規則第14A.07條，中海石油煉化為本公司的關連人士。此外， ...

本次注销控股子公司及不再参与高邮整市屋顶分布式光伏项目开发建设事项有利于公司进一步优化资源 配置、降低管理成本、提升经营质效。注销完成后，新能昊邮将不再纳入公司合并财务报表范围，不会 对公司财务状况和经营成果产生重大不利影响，不存在损害公司及公司股东、特别是中小股东利益的情 况。 格隆汇2月27日丨江苏新能(603693.SH)公布，公司拟注销控股子公司江苏新能昊邮新能源发展有限公 司。江苏国信高邮热电有限责任公司和博腾国际投资贸易有限公司为公司关联法人，分别持有新能昊邮 28%和20%股权，根据《上海证券交易所股票上市规则》等相关法律法规的规定，本次交易构成关联交 易。 ...

近日，石药集团公告披露，其非全资附属公司石药创新制药已于2月25日与关联方石药控股签署股权转 让协议，拟以2.3亿元价格出售所持北京国新汇金股份有限公司30.0704%股权，交易完成后石药集团将 不再持有该公司任何股份。 石药集团表示，此次出售旨在优化资源配置、聚焦制药核心业务，所得款项将用于补充石药创新制药日 常营运资金。集团预计本次交易将录得约1500万元亏损，该亏损系按交易对价扣减投资账面值估算得 出，最终以核数师审计结果为准。 （石药集团公告） 据悉，国新汇金主营全媒体传播业务平台运营，核心业务为移动财经资讯服务，并非石药创新制药的核 心业务板块。此次交易定价参考独立评估结果，以2025年6月30日为基准日，国新汇金股东全部权益评 估价值7.53亿元，对应标的股权评估值2.26亿元，最终交易价格较评估值略有溢价。财务数据显示，国 新汇金2025年营收4252.34万元，净亏损2693.58万元，其中下半年净亏1571.5万元，过渡期亏损将由受 让方承担。 (编辑：杨燕 林辰) ...

石药集团(01093)发布公告，于2026年2月25日，卖方石药创新制药股份有限公司(本公司非全资附属公 司，(股份代号：300765))与买方石药控股集团有限公司订立股权转让协议，内容有关买卖目标公司北京 国新汇金股份（300368）有限公司的30.0704%股权，代价为人民币2.3亿元。于出售事项完成后，卖方 及本集团将不再持有目标公司的任何股权。 目标公司主要从事全媒体传播业务平台的运营，该业务并不属于卖方的核心业务。出售事项乃基于对卖 方实际发展状况的全面考量。预期出售事项将有助于优化卖方的资源配置及财务结构;同时，此举可使 卖方专注于核心业务并降低营运风险，从而实现高质量发展，亦对本集团整体有利。 ...

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group (石药集团), has announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, which will allow the company to focus on its core business and optimize its financial structure [1]. Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1]. - The transaction is based on a comprehensive consideration of the seller's actual development status [1]. - The sale is expected to help optimize the seller's resource allocation and financial structure, allowing for a focus on core business and reduction of operational risks [1]. Group 2 - The target company primarily operates a full-media communication business platform, which is not part of the seller's core business [1]. - After the completion of the sale, the seller and the group will no longer hold any equity in the target company [1]. - This move is anticipated to contribute to the overall benefit of the group and facilitate high-quality development [1].

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, aiming to optimize resource allocation and focus on core business operations [1] Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1] - The transaction is expected to enhance the seller's financial structure and reduce operational risks [1] - The target company primarily operates in the full media communication business, which is not part of the seller's core operations [1] Group 2 - The completion of the sale will result in the seller and the group no longer holding any equity in the target company [1] - The decision to sell was based on a comprehensive assessment of the seller's actual development status [1] - This move is anticipated to facilitate high-quality development for the seller and benefit the overall group [1]

Group 1 - The company, Sailong Pharmaceutical Group Co., Ltd., will hold its third extraordinary general meeting of shareholders on March 5, 2026, in Changsha, Hunan Province, combining on-site and online voting [1][3][5] - The meeting will discuss a temporary proposal to continue the public transfer of the equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., which was submitted by the controlling shareholder, Hainan Yayi Gongying Technology Partnership [2][4][9] - The company has set the record date for shareholders to attend the meeting as March 2, 2026 [6][7] Group 2 - The company will provide a network voting platform for shareholders through the Shenzhen Stock Exchange, allowing them to vote online during specified times on March 5, 2026 [5][17][25] - The company has previously attempted to publicly transfer 100% of the equity of Hunan Sailong Biopharmaceutical Co., Ltd. but did not find qualified buyers during the initial offering period [33][34] - The starting price for the upcoming public transfer of the subsidiary's equity will be set at 78.255 million yuan, reflecting a 10% reduction from the previous offering price [34][44]

Group 1 - The company plans to publicly transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., to optimize resource allocation and improve operational efficiency [2][4] - The initial public offering price for the equity was set at RMB 86.95 million, based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [3][9] - The first public offering period ended without attracting any qualified buyers, leading the company to reduce the offering price by 10% to RMB 78.255 million for the next round of bidding [4][3] Group 2 - The subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., was established on July 19, 2017, with a registered capital of RMB 104.54 million and operates in drug production and sales [8] - The financial assessment indicated that the market value of the subsidiary's total equity was RMB 86.9439 million as of September 30, 2025 [9][10] - The company has completed a capital increase for the subsidiary, raising its registered capital from RMB 55 million to RMB 104.54 million as of January 14, 2026 [13] Group 3 - The board of directors approved the proposal for the public transfer of the subsidiary's equity, which will be submitted for shareholder approval [4][43] - The company aims to use the proceeds from the equity transfer to support its operational development, aligning with its strategic growth plans [15] - The company retains the right to terminate the transfer process if no qualified buyers are found after subsequent rounds of bidding [4][5]

Core Viewpoint - The company plans to sell its 100% stake in Profit Share Investments Limited for HKD 45 million, which will provide liquidity and allow for the reallocation of financial resources for future development [1] Group 1 - The sale is intended to provide an opportunity for the company to liquidate its investment in the target company [1] - The proceeds from the sale will be used to reduce the company's debt [1] - This transaction aligns with the company's overall strategic planning [1] Group 2 - The target company's sole asset represents approximately 4.62% indirect equity interest in the invested group [1] - The board believes that the sale will optimize resource allocation and strengthen the company's cash flow [1]